Image 1 of 2
Image 2 of 2
Discover the Revolutionary Impact of Tirzepatide
Tirzepatide, the innovative dual GIP and GLP-1 receptor agonist is transforming metabolic health by targeting appetite regulation, insulin sensitivity, and energy balance for profound results in type 2 diabetes management, obesity treatment, and beyond. Administered once weekly via subcutaneous injection, it delivers unmatched efficacy in clinical trials, empowering sustainable lifestyle changes and reducing chronic disease risks.
Exceptional Weight Loss and Body Composition Improvements: Delivers up to 20-23% body weight reduction over 72 weeks in adults with obesity, outperforming semaglutide with greater losses in weight and waist circumference—89-91% of participants achieve at least 5% loss, with benefits extending to preserved lean mass and reduced visceral fat for enhanced metabolic health.
Unrivaled Glycemic Control for Type 2 Diabetes: Reduces A1C by up to 2.5% with dose-dependent effects, improving insulin secretion and sensitivity while delaying gastric emptying—superior to comparators like dulaglutide, even in older adults without obesity or those with prediabetes to prevent progression.
Robust Cardiovascular Protection: Lowers 10-year CVD risk by 23.7% in obesity without diabetes, reducing major events like heart attack, stroke, and death by 13% versus dulaglutide—benefits seen across diverse subgroups and independent of weight loss, with similar strong outcomes to semaglutide in high-risk T2D patients.
Heart Failure and Kidney Support: Cuts risk of cardiovascular death or worsening heart failure by up to 20% in HFpEF with obesity, while slowing kidney disease progression and improving related outcomes in T2D—offering comprehensive cardiometabolic shielding.
Broader Metabolic and Quality-of-Life Gains: Enhances physical function, reduces inflammation and liver fat in conditions like MASH, and supports weight management in type 1 diabetes—boosting mobility, energy, and overall well-being for holistic vitality.
Supported by landmark 2025 trials like SURMOUNT-5, SUMMIT, and real-world analyses, tirzepatide redefines metabolic therapy as a powerful ally against obesity and its complications.
Wellness Store Disclaimer: We don't sell or prescribe medications. Instead, we connect you to licensed professionals who can guide your journey responsibly.
Because we are not the medical provider, there is a $20 clinical consult fee that is handled directly by the medical group during your intake—similar to a telehealth visit. Once the clinician approves your case and issues your prescription, that $20 fee runs automatically. This fee is separate from your Destination Regen Wellness Store Order. However, a $20 credit will automatically be applied in your cart to offset this required fee.
